-
2025-522805-39-00
4
2026-02-06
Phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit alpha
-
2025-522333-61-00
4
2026-01-23
Hidradenitis suppurativa
-
2025-521003-52-00
9
2025-12-19
HER2 Expressing Advanced Breast Cancer
-
2025-521843-19-00
4
2025-12-19
IDH1/2-mutated, ATRX-mutated and p53-mutated astrocytoma
-
2024-516148-24-00
5
2025-12-16
Down syndrome
-
2024-519913-76-00
4
2025-12-09
PDL1-negative metastatic triple-negative breast cancer
-
2025-521281-97-00
5
2025-12-02
Non-Small Cell Lung Cancer (NSCLC)
-
2024-518156-24-00
5
2025-11-10
Atopic Dermatitis
-
2025-520566-22-00
5
2025-11-10
Hormone Receptor-Positive, HER2-Negative Advanced/Metastatic Breast Ca
-
2024-519081-49-00
4
2025-10-28
Moderate to severe atopic dermatitis
-
2025-520564-17-00
5
2025-10-16
Hidradenitis suppurativa (HS)
-
2025-521640-38-00
5
2025-10-16
Focal onset seizures or primary generalized tonic-clonic seizures.
-
2025-521188-11-00
5
2025-10-15
Type 2 diabetes
-
2024-517633-40-00
5
2025-09-18
Hidradenitis Suppurativa
-
2024-512752-38-00
5
2025-09-09
Adjunctive and maintenance treatment to HCT
-
2024-519152-82-00
5
2025-09-03
Relapsed/Refractory Follicular Lymphoma
-
2023-508875-35-00
5
2025-09-01
Heart condition
-
2024-515098-93-00
5
2025-07-22
Myelodysplastic Syndromes (MDS), Chronic Myelomonocytic Leukemia (CMML
-
2024-517568-48-00
5
2025-07-21
Delayed Graft Function after Kidney Transplantation
-
2024-519322-20-00
5
2025-07-21
metastatic colorectal cancer
-
2024-518289-28-00
4
2025-07-04
Progressive pulmonary fibrosis [PPF]
Idiopathic pulmonary fibrosis [I
-
2024-515796-35-00
4
2025-06-26
Heart Failure with Preserved Ejection Fraction and Left Ventricular Hy
-
2024-516020-33-00
4
2025-06-26
Grave’s Disease
-
2024-515797-27-00
4
2025-06-25
Heart Failure with Reduced/Mildly Reducede Ejection Fraction and Left